Abstract
This study was conducted to compare the effects of two anti-VEGF-A drugs, Ranibizumab and Aflibercept, on the expression and secretion of VEGFs family members, and on their influence in proliferation and migration of endothelial cells (HECV) in vitro. HECV cells were exposed 24 h (T1), 4 days (T2) and 6 days (T3) to Ranibizumab or Aflibercept at pharmacodynamically relevant concentrations (Ranibizumab: 12.5 μg/ml and 125 μg/ml; Aflibercept: 50 μg/ml and 500 μg/ml). Cell viability and then expression and secretion of VEGF-A, VEGF-B, VEGF-C and PlGF were evaluated respectively by Real Time-PCR and ELISA. Intracellular signaling activated by VEGF-A and VEGF-C was investigated evaluating phosphorylation of VEGFR2. Influence in would healing was evaluated through scratch assay. In general no differences were observed among the tested concentrations of anti-vegf drugs. Ranibizumab and Aflibercept did not affect HECV cell viability in all experimental times. At T1, Ranibizumab decreased mRNA levels of VEGF-A, induced VEGF-C secretion, abrogated phosphorylation of VEGFR2 stimulated by VEGF-A, and impaired ability of HECV cells to repair wound healing. Aflibercept decreased mRNA levels of VEGF-A, -B and PlGF; slightly increased basal le...Continue Reading
References
Feb 1, 1992·Endocrine Reviews·N FerraraD W Leung
Sep 23, 2000·Nature·P Carmeliet, R K Jain
May 1, 2001·Nature Medicine·P CarmelietM G Persico
Apr 28, 2004·JAMA : the Journal of the American Medical Association·Neil M Bressler
Apr 28, 2004·The American Journal of Pathology·David M RobertsVictoria L Bautch
Dec 17, 2004·Pharmacological Reviews·Ann HoebenErnst A De Bruijn
Jan 22, 2005·Current Opinion in Genetics & Development·Peter BalukDonald M McDonald
Aug 18, 2005·Clinical Science·Hiroyuki Takahashi, Masabumi Shibuya
Jun 27, 2006·Investigative Ophthalmology & Visual Science·Magali Saint-GeniezPatricia A D'Amore
Oct 13, 2006·Retina·Napoleone FerraraRobert Kim
Feb 9, 2007·Journal of Clinical Pharmacy and Therapeutics·I Krämer, H-P Lipp
May 26, 2007·Investigative Ophthalmology & Visual Science·Peter HeiduschkaUNKNOWN Tübingen Bevacizumab Study Group
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·John S RudgeGeorge D Yancopoulos
Jan 15, 2008·Metabolism: Clinical and Experimental·Giorgio Luciano VivianiPatrizio Odetti
Sep 4, 2008·Cell and Tissue Research·Yongping Crawford, Napoleone Ferrara
Oct 18, 2008·Nucleic Acids Research·Paolo RomanoBarbara Parodi
Feb 27, 2009·Science Signaling·Yihai Cao
Apr 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Fan ZhangXuri Li
Jul 29, 2009·Nature Reviews. Clinical Oncology·Axel Grothey, Evanthia Galanis
Oct 14, 2009·Ophthalmology·Susan B Bressler
Oct 17, 2009·Investigative Ophthalmology & Visual Science·Suk Ho ByeonOh Woong Kwon
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Matthew Ohr, Peter K Kaiser
May 20, 2014·The British Journal of Ophthalmology·Deepika MalikBaruch D Kuppermann
Citations
Jul 26, 2017·British Journal of Cancer·Rajat BhattacharyaLee M Ellis
Jun 2, 2018·Journal of Cellular Physiology·Magda GharbiyaAlessandro Lambiase
Feb 6, 2018·Eye·Stefano FogliRomano Danesi
Jun 7, 2016·Journal of Neuroscience Research·Shubhangi PrabhudesaiSimon Geir Møller
Nov 25, 2016·Experimental and Therapeutic Medicine·Ming ZengJinxiong Xu
Jul 6, 2021·Journal of Biotechnology·María J LeivaRaquel Montesino